Biomarkers for efficacy of aliskiren as a hypertensive agent

Details Biomarkers for efficacy of aliskiren as a hypertensive agent Biomarkers for efficacy of aliskiren as a hypertensive agent

C - Chemistry, Metallurgy

12

Q

C12Q 1/68 (2006.01) A61K 31/165 (2006.01) A61P 9/12 (2006.01)

Patent

CA 2600525

A retrospective pharmacogenetic analysis was conducted in an attempt to evaluate potential association between genetic variation and outcome of a clinical trial of efficacy of aliskiren as an antihypertensive agent. Forty- eight polymorphisms were examined in twelve genes from the renin-angiotensin- aldosterone system (RAS) or previously implicated in blood pressure regulation. Significant associations were seen between one polymorphism in the angiotensin converting enzyme (ACE) gene, two polymorphisms in the angiotensin II type 2 receptor (AGTR2) gene, and clinical parameters of mean sitting diastolic and systolic blood pressure decrease. These effects were not found with irbesartan and placebo treatment, but instead were specific to aliskiren treatment.

Une analyse pharmacogénétique rétrospective a été effectuée dans tentative destinée à évaluer l'association potentielle entre la variation génétique et le résultat d'un essai clinique de l'efficacité de l'aliskirène en tant qu'agent anti-hypertensif. Quarante huit polymorphismes ont été examinés dans douze gènes du système rénine-angiotensine-aldostérone (RAS), ou impliqués antérieurement dans une régulation de pression sanguine. Des associations significatives ont été constatées entre un polymorphisme dans le gène de l'enzyme de conversion de l'angiotensine (ACE), deux polymorphismes dans le gène du récepteur de l'angiotensine II type 2 (AGTR2), et les paramètres cliniques de pression sanguine diastolique et systolique moyenne décroissent. Ces effets n'ont pas été trouvés lors du traitement avec l'irbesartan et un placebo mais, au contraire, furent spécifiques du traitement à l'aliskirène.

Affiliated with

Also associated with

Rating

Biomarkers for efficacy of aliskiren as a hypertensive agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biomarkers for efficacy of aliskiren as a hypertensive agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for efficacy of aliskiren as a hypertensive agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1884122